View
219
Download
0
Category
Preview:
Citation preview
7/30/2019 Medical Tribune May 2013
1/39
May 2013
www.medicaltribune.com
HPS2-THRIVE trial:
Negave results for
niacin
Low melatonin
secreon linked to
diabetes risk
NEWS
Managing wrist pain
IN PRACTICE
CONFERENCE
AFTER HOURS
Geng around on the
London Underground
Diabetes research failing to address
prevention
7/30/2019 Medical Tribune May 2013
2/39
2 May 2013
Diabetes research failing to address
prevention
Laura Dobberstein
The prevention of diabetes is being over-looked by diabetes researchers, accord-ing to a recent study.
Our descriptive analysis found that themajority of registered [diabetes] trials involvedrug therapies rather than preventative or
non-drug interventions, said study authorDr. Jennifer Green of Duke University Medi-cal Center in Durham, North Carolina, US,and colleagues.
Green and her team examined 2,484 in-terventional diabetes trials registered on theClinicalTrials.gov website between 2007 and2010, to beer understand which aspects ofthe disease were being addressed. [Diabetolo-
gia 2013; doi:10.1007/s00125-013-2890-4]
While 75 percent of the trials had a pri-marily therapeutic purpose, only 10 percentfocused on prevention. Sixty-three percent ofinterventions used drugs and only 12 percentlooked at modiable behaviors.
Their ndings also indicated some impor-tant demographic disparities of trials, whichtended to exclude children and the elderly,were oen small in size and duration, did
not geographically represent populations ofthose living with diabetes, and did not focuson signicant cardiovascular outcomes likeheart aack and stroke.
Twenty percent of adults over age 65 havediabetes, but less than 1 percent of the tri-als included patients in this age group. Mosttrials excluded patients over 75 years of ageand 30.8 percent excluded those over the ageof 65.
Four percent of trials targeted those un-der the age of 18. This low number of pedi-
atric trials may accurately reect the propor-tion of people in this age group aected bydiabetes. However, arguments exist as to whythis group should be beer represented inresearch. A 3 percent annual increase in type1 diabetes currently exists among those un-der the age of 18. In addition, children havea higher chance of developing complicationsduring their disease course and benet morefrom beer disease management than theirolder counterparts.
The small size and duration of the trialsconcerned the researchers. The average lengthof a trial was less than 2 years. Over half of alltrials had fewer than 100 participants and 91percent had fewer than 500 participants.
Complications like diabetic retinopathy,lower extremity amputation and end-stage re-
nal disease vary among ethnic groups, makingit important to include a diverse backgroundof people in diabetes research. Study popula-tions were overrepresented by patients fromNorth America, Western Europe and certainAsian countries, but underrepresented by pa-tients from other important regions such asRussia, Brazil and the Middle East.
Cardiovascular complications related to
diabetes have become an important researchtopic, particularly in relation to medicationdevelopment. Yet mortality and cardiovascu-lar complications were only reported in 1.4percent of trials.
The researchers concluded that currentclinical trials on diabetes research do not ade-quately address disease prevention, manage-ment or therapeutic safety. The results fromthis study build a beer understanding of on-
going research and could help direct futureresearch activities and resources.
7/30/2019 Medical Tribune May 2013
3/39
3 May 2013
Fast foods going cardio smart
Naomi Rodrig
Public education eorts promoting
healthy lifestyle for the prevention of
cardiovascular disease seem to be bear-
ing fruit as some fast food chains are moving
towards healthier menu options.
At the recent American College of Cardiol-
ogy (ACC) Annual Scientic Sessions in San
Francisco, California, US, Subway was pro-
moting heart-healthy meals, with detailed
nutritional information about its sandwich
and beverage choices. Subway was the rst
fast food chain to receive the American Heart
Associations (AHA) Heart Check certica-
tion by meeting AHAs criteria. Heart Check
meals contain
7/30/2019 Medical Tribune May 2013
4/39
4 May 2013 Forum
Conqering cardiovasclar disease
arond the globe
Excerpted from a keynote lecture by Dr. William Zoghbi, president of the American College
of Cardiology (ACC), during the 62nd Annual Scientic Sessions of the ACC, held recently in
San Francisco, California, US.
W
hen we think about overall cardio-
vascular care, we need to consider
all the elements. Certainly, rst
and foremost is the care of the patient with
heart disease. Of course there are many other
factors that we must consider and dedicate
our eorts to, starting with early detection of
disease, raising awareness about the impact
of obesity, inculcating healthy behaviors and
considering the contributions of genetic fac-
tors and, importantly, ethnic backgrounds.
We aim for beer care, beer population
health and aordable care from the perspec-
tive of both the patient and society.
The ACCs answer to achieving this triple
aim has emphasized quality, value and pro-
fessionalism. The college has also focused on
patient-centered care and is seeking collabo-
rations among organizations for the develop-
ment of guidelines, quality tools and health
policies.Key ACC initiatives to help advance car-
diovascular health include data registries and
their impact, appropriate use of diagnostic
modalities and interventions, strategies to
empower patients with knowledge, and ap-
proaches to deal with public health challeng-
es, both locally and globally.
National data registries provide important
data on practice of medicine and patient out-comes. The ACCs National Cardiovascular
Data Registry, or NCDR, celebrates its 15thyear this year and it has become the ag-
ship of registries, growing to a total of seven
registries. These cover most areas of cardiol-
ogy, including interventional cardiology, im-
plantable cardioverter debrillator therapy,
management of acute myocardial infarction,
congenital heart disease and, most recently,
transcatheter valve therapy. These continual-
ly enrolling registries have more than 24 mil-lion records.
7/30/2019 Medical Tribune May 2013
5/39
5 May 2013 Forum
What is also exciting is that some of these
registries have gone global, with presence in
Asia, the Middle East and South America.
This enables sharing and comparing of car-
diovascular care quality between nationsworldwide with the goal of improving car-
diovascular care.
Our most recent partnership with the So-
ciety for Thoracic Surgery, as well as regula-
tory agencies, payers and industry, ushers in a
new registry paradigm this one for patients
with advanced aortic stenosis mandating
participation for reimbursement while moni-
toring quality, patient outcome and support-
ing research and innovation.
The power of data reporting can change
clinical practice and improve quality of care.
Before reporting door-to-balloon data for
treatment of acute heart aack, most hospi-
tals and physicians believed they were do-
ing a great job in this type of care. With the
data, the percent of patients achieving a door-
to-balloon time of less than 90 minutes im-
proved. Such data also lowered the rate of in-
appropriate angioplasties in favor of medical
treatment.
Reecting on the application of knowledge,
while science tells us what we can do, guide-
lines tell us what we should do, and registries
show us what we are actually doing and will
likely be doing in the future.A key component of high-quality care plac-
es an emphasis on the patient. This is where
we need to be spreading the word about
healthy living and healthy choices in the com-
munity.
On one hand, looking back on the impact of
cardiovascular interventions and outcomes, it
is really gratifying to see the signicant de-
cline in cardiovascular mortality in the USover the past 40 years, thanks to advances in
research, medications, devices and catheter-
based and surgical interventions.
However, many challenges remain. In the
US, many patients who need to take aspirin
are not. And many are in need of beer bloodpressure control and cholesterol manage-
ment. Smoking rates, although beer than in
other countries, are still far from optimal.
Even more urgent are challenges looming
globally. Death from cardiovascular disease
exceeds that from any other disease and ac-
counts for about one-third of total deaths
worldwide. It is higher than cancer, respira-
tory disease and diabetes, the other main non-
communicable diseases (NCDs), combined.
The projected trends are alarming as they
gradually increase for both cardiovascular
disease and cancer.
There are 10 highest risk factors for cause of
total death worldwide. The most important is
high blood pressure followed by tobacco use,
high glucose, physical inactivity, overweight
and obesity, and high cholesterol. Many of
these risk factors are the same for other NCDs.
Therefore, addressing them will have a major
impact on global health, not only cardiovas-
cular health.
Prompted by the NCD Alliance, the United
Nations had its rst ever high-level meeting
on NCDs in September 2011. The outcome of
the summit was a political declaration thatcalled on the World Health Organization to
establish global targets for curbing NCDs. In-
deed, the World Health Assembly met in Ge-
neva in May 2012 and approved a monumen-
tal goal: a 25 percent reduction in premature
mortality from NCDs by the year 2025.
To achieve that overall goal, the following
targets were adopted: reductions in tobacco
smoking, physical inactivity, excessive alco-hol use, salt intake, raised blood pressure,
7/30/2019 Medical Tribune May 2013
6/39
6 May 2013 Forum
diabetes and obesity. Availability of essen-
tial medications to prevent heart aack and
stroke was also emphasized.
Going forward, there are challenges but
great opportunities to reach this ultimategoal. As risk factors are so prevalent and tra-
ditional treatments are aordable, there is no
need for new inventions globally.
A big challenge is implementing the reso-
lutions of various targets, knowing these may
vary by nation. It is crucial to establish beer
funding for the NCD movement currently
NCDs cause about 60 percent of global deaths
yet receive about one percent of health fund-
ing. So the time is now for us to act and work
collaboratively.Cardiovascular disease is a global prob-
lem. We can protect population health by
taking a global perspective and working to-
gether with ACC chapters and national and
international organizations to reach this no-
ble goal.
7/30/2019 Medical Tribune May 2013
7/39
7 May 2013 Conference Coverage
Preventing cardiovasclar disease: Do thevery elderly reqire a different approach?
62nd Annual Scientifc Sessions o the American College o Cardiology, 9-11 March, San Francisco,
Caliornia, US
Excerpted from a lecture by Dr. Janice Schwartz, clinical professor of Medicine, Bioengineering,
and Therapeutic Science at the University of California, San Francisco, US, during the 62nd
Annual Scientic Sessions of the American College of Cardiology, held recently in San
Francisco, California, US.
When I rst thought about whether
the very elderly require a dier-
ent treatment approach, I said yes.
Its obvious, there is no question we should
be treating elderly patients dierently than
younger patients.
I think the individual treatment goals
might dier as you have older patients. They
certainly have more comorbidities and those
are going to inuence our choices and limit
our options. And clearly cost limits the op-
tions elderly women in the US have the
highest level of poverty of any group. But if
the goal is the best therapy for each patient,
then we have the same goal for all patients.
However, maybe the approach should be
to choose options and therapy that benet thepatient in their life span. Im going to dene
benet as meeting the goals of the patient and
improving the function or quality of life that
is a wonderful goal and cardiologists are com-
ing around to that. We no longer look at just
prolongation of life as a good outcome, were
willing to say fewer hospitalizations and de-
creases of morbidity are a valid goal.
Im also going to introduce the conceptthat we would like to prevent decline in de-
pendency. If you ask your patients and give
them informed consent before procedures,they might tell you they dont mind dying but
Regular activity in the very elderly improves quality of life andlife expectancy.
7/30/2019 Medical Tribune May 2013
8/39
8 May 2013 Conference Coverage
they dont want to wake up with a stroke and
be dependent.
Consider life expectancy over patient age
When we think about diseases and risk fac-tors, we really have a goal of treatment, and
we can do it in the middle-aged and younger
patients. The goal is prolonging their life.
But as people get older, the things that be-
come important are quality of life and mainte-
nance of function. The challenge is, of course,
when were going to start shiing from think-
ing about life prolongation to quality of life
and function.
The key concepts that provide a framework
for decision making are to estimate life expec-
tancy in the elderly and very elderly, recog-
nize the importance of function and the lag-
time until benet or harm of therapies, and
patient-centered decisions.
Data from the US Census Bureau show
that an 85-year-old man might have on aver-
age 5.7 years to live, a 90-year-old has another
4 years to live and if you make it to 100 you
will probably live another 2 years, on aver-
age. For women those years are even longer.
The 85-year-old might be living out to about
7 years, the 90-year-old has another ve years
and the 100-year-old is going to have about
2.3 years.
But thats average life span and, as the
economist Milton Friedman said: Never try
to walk across a river just because it has anaverage depth of four feet.
In an average life span for people between
70-90 years, there is considerable variability.
So I think we have to do a beer job when we
come to individual decisions about our pa-
tients to try and project their life span.Traditional risk calculators such as the
Framingham risk score and the Reynolds risk
score do not help decision making for the el-
derly.
Risk factors that are important in the older
group are age, sex, body mass index, the pres-
ence of chronic diseases, smoking, diculty
with the activities of daily living, managing
nances, the ability to walk several blocks,
and trouble pushing large objects.
Prognosis calculators that weigh these in-
dicators for the elderly might show that the
odds of dying within 4 years for someone
who does not have diabetes or is overweight
and doesnt have cancer or smoke but has dif-
culty bathing or with other activities of daily
living might be 59 percent. However, the ad-
dition of congestive heart failure to a person
with this prole would only increase the odds
of dying within 4 years to 64 percent.
The things that drive life expectancy in this
group are really the activities of daily living
bathing, dressing, managing nances, and so
on certainly much more so than heart failure.
Similar risk calculators for this group in-
clude determining whether patients havebeen hospitalized, if they can read a news-
paper, do they have hearing impairment or
weight loss, are they receiving home care ser-
vices and whether they are poor.
So if the risk factors are dierent, should
treatment be dierent?
Treat with life span in mind
As an example, one trial compared statintherapy with placebo in 5,804 patients aged
The challenge is, of course,
when were going to start shiing
from thinking about life prolongation
to quality of life and function
7/30/2019 Medical Tribune May 2013
9/39
9 May 2013 Conference Coverage
70-82 years over 4 years with a history or risk
of vascular disease. [Lancet 2002;360:1623-
1630] Even by the time one begins to see ben-
ets from the statin, the risk of death or car-
diovascular events remains almost the same,and certainly up to 2 years. So I would say
someone with a life expectancy less than 2
years is not going to benet and therapy may
well hurt them, it will certainly cost more.
If we also look at the evidence for aspirin
for primary prevention, we see aspirin re-
duces the risk of myocardial ischemic events,
with a higher rate of bleeding, according to
one study, and does not prolong life. Again,
the treated time-to-benet is not until 3.7-10
years out. [Lancet 2009;373:1849-1860]
Here patients may not live that long so
they dont get the potential benet, there is
no dierence in cardiovascular mortality but
bleeds happen earlier and they risk hemor-
rhagic stroke.
The American Geriatric Society says yes,
the elderly require dierent approaches, for
example, when picking medications for hy-
pertension, using aspirin for primary pre-
vention of cardiac events, using potentially
inappropriate drugs with caution and advise
against tight glucose control, calling moder-
ate control beer.
Make exercise a priority
The one thing that helps everything a pa-
tient has is exercise. We should be the leaders
in developing exercise programs that are go-
ing to benet the whole patient, especially theolder patient. It doesnt need to be intense ex-
ercise like it should be for cardiovascular ben-
et in middle-aged men. There are no short-
term adverse eects, there is a short lag-time
for benet and the benets hit the body both
above and below the waist.
The US National Institutes of Health says
regular activity improves quality of life, ex-
tends life and decreases the risk of cardiovas-
cular disease and other illnesses and disabili-
ties.
To conclude, they key considerations for
the very elderly are estimated life expectancy
not age alone lag-time to potential benet
and adverse treatment eects and burden.
Estimates of benets and harms should be
weighted with qualitative judgments of indi-
viduals values and preferences. Function and
not cardiovascular risk factors have the great-
est impact on life expectancy and quality of
life in the very old. And we must focus on im-
proving function with exercise and prevent-
ing the conditions that decrease function and
quality of life.
7/30/2019 Medical Tribune May 2013
10/39
10 May 2013 Conference Coverage
Cangrelor otperforms clopidogrel
dring PCI
62nd Annual Scientifc Sessions o the American College o Cardiology, 9-11 March, San Francisco,
Caliornia, US
Elvira Manzano
T
he new anti-cloing agent cangrelor,
given during percutaneous coronary
intervention (PCI), performed beer
than mainstay drug clopidogrel at reducingischemic events, according to results from the
CHAMPION PHOENIX* trial.
Cangrelor signicantly reduced the pri-
mary endpoint of composite rate of death,
myocardial infarction (MI), ischemia-driven
revascularization and stent thrombosis by
22 percent at 48 hours post-randomization
(p=0.005) without an increased risk of severe
bleeding (p=0.44). This benet was drivenby a 20 percent reduction in the rate of acute
MI and a 38 percent reduction in the inci-
dence of stent thrombosis. [N Engl J Med 2013;
doi:10.1056/NEJMoa1300815]
Cangrelor may be an aractive option
across the full spectrum of patients undergo-
ing PCI, said rst study author Dr. Deepak L.
Bha from the VA Boston Healthcare System
and Brigham and Womens Hospital in Bos-ton, Massachuses, US. Unlike clopidogrel,
cangrelor takes eect rapidly and wears o
within an hour of infusion, which allows for
exibility to initiate and stop ADP inhibition
immediately in patients requiring urgent sur-
gery or in those who develop bleeding com-
plications, Bha added.
Despite being a more potent antithrom-
botic than the comparator, there was no bad
bleeding that would be worrisome when add-
ing another drug into the medical regimen,
said Dr. Robert Harrington of Stanford Uni-
versity School of Medicine in California, US,
and co-principal investigator of CHAMPION
PHOENIX.
CHAMPION PHOENIX is a randomized,
double-blind, all-comer trial involving11,145 patients with acute coronary syndrome
(stable angina, non-STEMI or STEMI) or other
conditions requiring urgent or elective PCI,
randomized to a bolus and infusion of can-
grelor or a loading dose of oral clopidogrel
(600 mg or 300 mg).
Overall, procedural complications were
less common with cangrelor (3.4 percent vs
4.5 percent; p=0.002) as well as the need for
rescue therapy with glycoprotein IIb/IIIa in-
Cangrelor successfully reduced ischemic events without increased risk ofsevere bleeding, but it wont be routine therapy for all PCI patients yet.
7/30/2019 Medical Tribune May 2013
11/39
11 May 2013 Conference Coverage
hibitors (p
7/30/2019 Medical Tribune May 2013
12/39
12 May 2013 Conference Coverage
HPS2-THRIVE randomized 25,673 high-
risk heart patients from Europe and China to
a combination of ER niacin/laropiprant or a
placebo. All patients received standard low-
density lipoprotein (LDL) lowering therapyconsisting of simvastatin with or without
ezetimibe.
The most striking aspect of the trial was the
excess of serious adverse events as a result of
niacin therapyevents signicant enough to
result in hospitalization or signicant illness,
which went beyond the well- known side ef-
fects of niacin.
Over the course of the 3.9-year study, there
were 31 serious adverse events per 1,000 nia-
cin-treated patients.
Compared with placebo, niacin resulted in
an excess of 3.7 percent diabetic complications,
1.8 percent new-onset diabetes, 1.4 percent in-
fections, and 1 percent gastrointestinal adverse
events (p
7/30/2019 Medical Tribune May 2013
13/39
13 May 2013 Conference Coverage
Long-term otcomes of TAVR, srgery
similar in severe aortic stenosis
62nd Annual Scientifc Sessions o the American College o Cardiology, 9-11 March, San Francisco,
Caliornia, US
Elvira Manzano
Transcatheter aortic valve replacement(TAVR) remains comparable to openheart surgery in the long term in pa-
tients with severe aortic stenosis at high riskfor surgery, according to the updated resultsof the PARTNER* trial, but mortality rateswith both approaches are high.
At 3 years, there was no statistical dierencein the primary endpoint of all-cause mortality
between the two groups 44.2 percent withTAVR and 44.8 percent with open heart surgery.Stroke rates were also no dierent at 8.2 percentand 9.3 percent, respectively. Paravalvular leaks
or regurgitation were persistent and fatal.TAVR should be considered an alternative
to surgery with similar mortality and othermajor clinical outcomes, said study present-er Dr. Vinod Thourani from Emory Univer-sity School of Medicine in Atlanta, Georgia,US. Future eorts should be directed towardreducing TAVR-procedure-related complica-tions, including strokes, vascular events and
paravalvular regurgitation.One-year results from the PARTNER A
trial, presented 2 years ago, showed similarmortality outcomes for TAVR and surgery.However, strokes and transient ischemic at-
tacks (TIA) were signicantly higher withTAVR. The trial was extended to assess long-term outcomes and valve performance. At 2years, even mild paravalvular regurgitationwas associated with increased mortality.
PARTNER A included 699 patients (medi-an age, 84.1) enrolled between May 2007 and
September 2009 and randomized to catheter-based procedure either through transapicalor transfemoral access or surgery. At 3 years,there were more major vascular complica-tions with TAVR (12.5 percent vs 3.8 percent;p
7/30/2019 Medical Tribune May 2013
14/39
14 May 2013 Conference Coverage
On- vs off-pmp CABG: Patient factors,
srgical expertise are ey
62nd Annual Scientifc Sessions o the American College o Cardiology, 9-11 March, San Francisco,
Caliornia, US
Dierent types of CABG surgery continue to show mixed outcomeresults.
Naomi Rodrig
T
hree late-breaking clinical trials com-
pared on-pump versus o-pump coro-
nary artery bypass gra (CABG) sur-
gery, reporting mixed outcomes, according tostudy population.
On-pump CABG is less demanding surgi-
cally but more expensive, requiring a heart-
lung machine and disposable components.
Conversely, the less costly o-pump or beat-
ing-heart procedure requires a higher degree
of surgical expertise. Previous trials compar-
ing the two techniques reported conicting
results, and o-pump procedures have be-come less popular during the past decade, es-
pecially in developed countries.
The German O-Pump CABG in Elderly
Patients (GOPCABE) study randomized 2,539
patients aged 75 years undergoing elective,
rst-time CABG to on- or o-pump surgery.
There was no signicant dierence in the
primary composite endpoint of death, stroke,
myocardial infarction (MI), repeat revascu-larization or new renal replacement therapy
within 30 days of surgery between the two
arms [8.2 vs 7.8 percent; p=0.74], reported
Dr. Anno Diegeler of the Heart Center Bad
Neustadt, Bad Neustadt, Germany. Results
for all components of the primary endpoint
were similar between the groups at 30 days,
and there was also no signicant dierence in
the rate of the primary endpoint at 12 months
(14.0 vs 13.1 percent; p=0.483).
Our data showed that CABG can be per-
formed in the elderly population with excel-
lent results, and this is equally true for bothtechniques. The less costly o-pump surgery
may be benecial in developing countries,
he said.
CORONARY the largest trial to compare
the two procedures examined the composite
of death, stroke, MI or new kidney failure in
4,752 patients scheduled to undergo CABG.
As reported previously, there was no dier-
ence between patients receiving the o-pump
and on-pump surgery at 30 days (12.2 vs 13.3
7/30/2019 Medical Tribune May 2013
15/39
15 May 2013 Conference Coverage
percent; p=0.24). We now found that both
on-pump and o-pump bypass have similar
results even at 1 year, said lead investigator
Dr. Andre Lamy of McMaster University in
Ontario, Canada. The rates of coronary re-vascularization were also similar between the
groups.
While neurocognitive decline might be
more prominent with on-pump surgery, the
researchers found only a transient improve-
ment in neurocognitive function among those
receiving o-pump CABG. At 1 year, our
results were similar with both techniques, as
was quality of life, he said.
In contrast, the single-center PRAGUE-6
trial, which randomized 206 high-risk pa-
tients (EuroSCORE 6) to receive on- or o-
pump CABG, found a signicantly lower rate
of the primary endpoint among patients re-
ceiving the o-pump procedure (9.2 vs 20.6
percent; p=0.028). Furthermore, a signicant-
ly higher percentage of on-pump patients re-
quired a blood transfusion (80.2 vs 64.9 per-cent; p=0.017).
Our study shows that surgical revascular-
ization without using the heart-lung machine
can be benecial for high-risk patients, espe-
cially older ones with many other disorders
or diseases, concluded Dr. Jan Hlavicka, of
Charles University in Prague, Czech Republic.
All investigators stressed that risk assess-
ment and surgical expertise are key factors
aecting patient outcomes. Therefore, sur-
geons should tailor their surgical approach to
their technical expertise and expected techni-
cal diculty, suggested Lamy.
7/30/2019 Medical Tribune May 2013
16/39
7/30/2019 Medical Tribune May 2013
17/39
17 May 2013 News
Srgery tops medical therapy for obese
diabetics
Bariatric surgery is a treatment option to beer manage obese diabetics.
Elvira Manzano
Bariatric surgery improved glycemic
control beer than optimal medical
therapy alone in obese patients with
type 2 diabetes independent of weight loss,
two randomized trials have shown.
In the larger of two trials (STAMPEDE*),
HbA1c levels normalized to 6 percent by 1
year, the primary endpoint, in 42 percent and
37 percent of patients who underwent gastric
bypass and sleeve gastrectomy, respective-
ly, compared with 12 percent in those who
received intensive medical therapy alone
(p=0.002 and p=0.008).
Average weight loss was greater aer surgi-
cal procedures than aer medical therapy (60
lbs vs 10 lbs). Medication use to control lip-
ids, glucose and blood pressure also dropped
signicantly aer surgical procedures, but in-
creased with medical therapy alone. [N Engl J
Med 2012;366:1567-1576]
STAMPEDE included 150 obese patients
(BMI, 27-43 kg/m2) with uncontrolled type 2
diabetes randomized to Roux-en-Y surgery or
sleeve gastrectomy, or medical therapy alone.All patients received intensive medical thera-
py (lifestyle counseling, weight management,
glucose monitoring and newer diabetes drugs)
prior to randomization. BMI, body weight and
insulin resistance improved signicantly in
those who underwent bariatric surgery.
The take home message is that surgical
patients enjoyed not only signicant or supe-
rior improvement in glycemic control but didso on much lower regimens of diabetic and
cardiovascular medications, said STAM-
PEDE study author Dr. Philip R. Schauer from
Cleveland Clinic, Ohio, US.
In a second trial, bariatric surgery resulted
in greater reductions in fasting glucose and
HbA1c levels aer 2 years than did medical
therapy. Seventy-ve percent of patients on
gastric-bypass and 95 percent on biliopan-
creatic-diversion (p
7/30/2019 Medical Tribune May 2013
18/39
18 May 2013 News
conventional medical therapy (medication,
strict diet and lifestyle interventions), or gas-
tric bypass surgery or biliopancreatic diver-
sion.
Both studies targeted an HbA1c level of
7/30/2019 Medical Tribune May 2013
19/39
19 May 2013 News
Radha Chitale
Women who produce low levels of
nocturnal melatonin are more than
twice as likely to develop type 2
diabetes independent of other major diabetes
risk factors, according to a recent observation-
al study.
The case-controlled study drew data from
a cohort in the US Nurses Health Study and
included women who provided urine and
blood samples at baseline in 2000. Over 12
years, 370 women developed type 2 diabetes
and the researchers matched these subjects
with an equal number of controls. [JAMA
2013;309:1388-1396]
The researchers measured melatonin se-
cretions indirectly using creatinine as a proxy
marker. The median urinary melatonin-to-
creatinine ratio among controls was 36.3 ng/
mg, which was higher than the median ratio
of the diabetic group (28.2 ng/mg).
Women in the diabetes group were divided
into three groups of low, medium and high
melatonin secretors. The median urinary mel-
atonin-to-creatinine ratio was 67 ng/mg amonghigh melatonin secretors compared with 14.4
ng/mg among the low-secretion group.
Women with low levels of nocturnal mela-
tonin were 2.2 times more likely than high
melatonin-secreting women to develop type 2
diabetes. The researchers controlled for body
mass index, lifestyle and location factors,
menopause, history of diabetes, hypertension,
use of beta blockers or non-steroidal anti-in-ammatory drugs and diabetes biomarkers.
Lead researcher Dr. Ciaran J. McMullan of
Brigham and Womens Hospital, Boston, Mas-
sachuses, US, said the results translated to
9.3 cases of diabetes per 1,000 patient-years
among low-secreting women compared with
4.3 cases among high-secreting women.
Normally, melatonin levels tend to be low
throughout the day, rise in the evening, pla-
teau while sleeping and drop upon waking.
Prior studies have shown that insulin resis-
tance and type 2 diabetes is associated with loss-
of-function mutations in melatonin receptors.
McMullan said the data suggests that en-
dogenous levels of melatonin may be part
of the pathogenesis of diabetes, however the
wide variation in melatonin secretion levelsmakes unraveling the connection dicult.
The question remains as to whether mela-
tonin could be a modiable risk factor for the
prevention or possibly treatment of type 2 di-
abetes, endogenously through dark exposure
or exogenously through oral supplements,
the researchers noted.
Further studies on dierent populations,
including men and other ethnic groups, mayalso be indicated.
Lo melatonin secretion lined to
diabetes ris
Melatonin may play a role in the pathogenesis of type 2 diabetes.
7/30/2019 Medical Tribune May 2013
20/39
20 May 2013 News
Telehealth not cost-effective, stdy shos
Radha Chitale
Telehealth may not be the cost-saving
model of care its been touted as, a new
study from the UK shows.
Quality of life was no dierent for chroni-
cally ill patients who tacked telehealth mea-
sures onto their standard supportive care
compared with similar patients who received
usual care.
Telehealth encompassed digital telemoni-
toring of patient vital signs, in real time or
saved for later access, as well as telephone
support, during which healthcare profession-
als could also monitor and track vitals, and
added to the overall costs for patients that re-
ceived it.
The QALY [cost per quality adjusted life
year] gain by patients using telehealth in ad-
dition to usual care was similar to that by
patients receiving usual care only, and total
costs associated with the telehealth interven-
tion were higher, the researchers said.
A group of 965 patients from a larger tele-
health trial were eligible for inclusion in this
questionnaire study on health outcomes.
These patients had to have at least one of
three chronic diseases: chronic obstructivepulmonary disease, heart failure or diabetes.
[BMJ2013;346:f1035]
Patients were randomized to telehealth in-
tervention (n=534) or to usual care (n=431).
QALY for telehealth plus usual care was
92,000 (S$174,000), which is well above the
UK National Institute for Health and Clinical
Excellence threshold of 30,000 (S$57,000), theresearchers said.
Even factoring in an 80 percent reduction
in equipment costs and higher working ca-
pacity, analysis showed that telehealth would
probably be eective, to 61 percent for a will-
ingness to pay 30,000 per QALY.
Telehealth was designed to have a num-
ber of benets to both patient and doctor,
including allowing patients to be more inde-
pendent and spend less time actively seek-
ing monitoring or care. Doctors can monitor
patients blood pressure or glucose levels, for
example, without scheduling unnecessary
visits.
These types of measures were thought
to reduce healthcare costs through fewer
doctor appointments and avoiding unnec-
essary treatments in favor of more effective
ones, particularly for patients with chronic
diseases. However, little quality data exist
on the association between outcomes and
costs.
Management of people with long-term
conditions is under the spotlight, given the
rapidly growing prevalence of such conditions
in aging populations, the researchers said.They added that the study raises further is-
sues such as targeting telehealth towards spe-
cic subgroups and the eects of livelihood
and demographics on telehealth ecacy and
costs that should be reviewed in subsequent
analyses.
7/30/2019 Medical Tribune May 2013
21/39
21 May 2013 News
Freqent home relocations lined to
behavioral problems in some children
Laura Dobberstein
Moving to a new home more than
three times in the rst 5 years of
life may increase aention and
behavioral problems in economically disad-
vantaged children, according to a recent US
study.
Previous studies have linked frequent
moving to reduced academic performance,
greater rates of high school dropout, poorer
emotional and behavioral outcomes and low-
er levels of educational aainment.
Developmental psychologists have
shown that the home environment is one of
the most important inuences on young chil-
drens school readiness, noted study author
Dr. Kathleen Ziol-Guest, postdoctoral associ-
ate at Cornell University, Ithaca, New York,
US, and colleagues.
Ziol-Guest and her team examined data of
2,810 American children born between 1998
and 2000 from an existing study on new par-
ents and the welfare of their children. The par-
ents were interviewed at the hospital shortly
aer giving birth. Follow-up interviews weresubsequently conducted by telephone when
the child was 1, 3 and 5 years of age. In-home
assessments were also done when the child
was 3 and 5. The assessments included an in-
terview with the mother, an evaluation of the
home environment and an appraisal of the
childs health and development. [Child Dev
2013; doi: 10.1111/cdev.12105]
At the 5-year assessment, vocabulary andword identication tests determined lan-
guage and literacy outcomes and a checklist
monitored behavioral diculties.
Child gender, race, socioeconomic status
and parental education level and other de-
mographics were examined. Residential in-
stability was dened as moving at least three
times in the rst 5 years of a childs life, and
poverty was dened by the ocial federal
threshold.
Seventy-seven percent of the children in
the study had experienced at least one move
and 29 percent were residentially instable. Of
those dened as having residential instability,
44 percent were below the poverty threshold.
Residential instability was linked to aen-
tion problems, anxiousness, depression, ag-
gressiveness and hyperactivity among 5-year-
olds living in poverty. Language and literacy
outcomes and those who were not categorized
as poor were not aected by moving.
The authors speculated that frequent
moves may disrupt a childs socio-emotional
development. Social networks may also be
disrupted, creating an extra challenge for chil-
dren to make new friends. Feelings of frustra-
tion or anger may be displayed as behavioralproblems while test scores are less directly af-
fected.
Low-income families may move for dif-
ferent reasons than higher-income families,
they explained.
While some families choose to move be-
cause they are dissatised with their old
neighborhood or home, others have to move
in search of work, less expensive housing, oreven due to evictions and foreclosures.
7/30/2019 Medical Tribune May 2013
22/39
22 May 2013 News
Speaking to Medical Tribune, Dr. Sun-
ny Im-Wang, pediatric psychologist and
school psychologist in San Francisco, Cali-
fornia, US, and author of Happy, Sad, &
Everything In Between: All About My Feel-ings said: Usually, frequent changes and
inconsistent environment [are] not good
for young children, adding that not all
children experiencing multiple moves will
have behavioral issues.
With lower-income families, the stress of
nancial issues puts burden on the family,which also impacts childrens behavior due to
familys stress, said Im-Wang.
7/30/2019 Medical Tribune May 2013
23/39
23 May 2013 News
Vitamin D deficiency a concern for idney
transplant patients
Laura Dobberstein
Kidney transplant patients with vita-
min D deciency should consider tak-
ing vitamin D supplements in order
to prevent a decline in kidney function, say
French researchers.
Vitamin D is a critical hormone control-
ling mineral homeostasis, said Dr. Frank
Bienaime of the Universit Paris Descartes
and INSERM and Assistance Publique
Hopitaux de Paris, France, and colleagues.
It promotes phosphate and calcium ab-
sorption by the gut and increases calcium
reabsorption by the renal distal tubule,
thereby providing the positive calcium and
phosphorus ux required for bone mineral-
ization.
Bienaime and his team studied 634 pa-
tients who underwent a kidney transplant
to beer understand vitamin D levels at 3
months aer transplantation. The study ex-
amined vitamin D status in relation to early
mortality or transplant loss, the eciency
of the kidneys at 12 months as measured by
ow rate, and the health of the kidneys mea-sured through scarring and atrophy between
3 and 12 months.
The patients were evaluated over a 2- to
4-month period aer receiving the transplant.
The ow rate of ltered uid through the
kidney, known as glomerular ltration rate
(GFR), and vitamin D levels were measured.
Blood and urine samples were analyzed for
content and biopsies were examined for tu-
bular atrophy and scarring. [J Am Soc Nephrol
2013; Mar 28. Epub ahead of print]
During the course of the study, 19 of the pa-
tients were lost to follow-up, 30 patients lost
their transplanted kidney, 28 patients died
with a functioning transplant, and 3 died af-
ter losing their transplanted organ. Infection
was the most common cause of death and was
seen in 12 patients.
Deciency in vitamin D was shown to
correlate with lowered kidney function at 3
months aer transplant and increased kid-
ney scarring at 12 months aer transplant.
Other hormones associated with mineral me-
tabolism like calcium, phosphorus, calcitriol,
parathyroid hormone or broblast growth
factor-23 were not linked to kidney health.
Vitamin D deciency is a common problem
among those with impaired kidney function
but the status of the hormone aer having a
kidney transplant is not well understood.
The study authors encouraged future re-
search to evaluate the use of vitamin D sup-
plements in kidney transplant patients.[Our results] suggest that maintaining
vitamin D concentration within the normal
range would prevent renal function deterio-
ration aer renal transplantation, said Bein-
aime. Vitamin D supplementation, a simple
and inexpensive treatment, may improve
transplantation outcomes.
7/30/2019 Medical Tribune May 2013
24/39
24 May 2013 Drug Profile
Dtasteride/tamslosin: Combination
therapy for BPH
The true prevalence of benign prostatic hyperplasia (BPH) in male populations has been
dicult to estimate due to the lack of a standardized denition. However, the characteristic
features of BPH abnormal proliferation of stromal and epithelial prostatic cells become
more common in men with age. The following article highlights the benets of dutasteride/
tamsulosin (Duodart, GlaxoSmithKline), a combination treatment consisting of two drugs
with complementary mechanisms of action, in patients with BPH.
Naomi Adam, MSc (Med),Category 1 Accredited Education Provider
(Royal Australian College of General Practitioners)
Introduction
Benign prostatic hyperplasia (BPH) is a
non-cancerous enlargement of the prostate
gland. Clinically, patients with BPH present
with lower urinary tract symptoms (LUTS) either voiding symptoms (eg, weak stream,
hesitancy, intermiency and abdominal
straining), and/or storage symptoms (eg, fre-
quency, nocturia, urgency and urge inconti-
nence). Voiding symptoms are more common
while storage symptoms are more bother-
some and interfere more with daily activities.
However, not all men with BPH suer from
LUTS, and conversely, not all men with LUTShave BPH.
The lack of a standardized denition of
BPH means that it is dicult to estimate its
true prevalence. In an aging male popula-
tion ( 80 years), the characteristic histologi-
cal features of BPH abnormal proliferation
of stromal and epithelial prostatic cells are
extremely common, seen in up to 80 per-
cent. When present, the symptoms can be
extremely bothersome and become more so
over time as the prostate enlarges and the
condition progresses. Eventually, complete
blockage of the urethra, known as acute
urinary retention (AUR), may occur. AUR
is a medical emergency that is oen unex-pected, painful and requires catheterization
to treat it. Following a rst episode of AUR,
the condition oen recurs, and 24 to 42 per-
cent eventually go on to have prostatectomy
surgery.
Guidelines developed at the 6th Interna-
tional Consultation on New Developments
in Prostate Cancer and Prostate Diseases
provide an algorithm for the management
of LUTS in men in the primary care seing.
7/30/2019 Medical Tribune May 2013
25/39
25 May 2013 Drug Profile
[Male Lower Urinary Tract Dysfunction: Evalu-
ation and Management, 2006] The rst step is a
series of simple tests, and key among these is
the question as to whether patients nd their
symptoms bothersome. A large proportion ofmen who present are simply seeking reassur-
ance. Reports in the lay media oen errone-
ously state that geing up to urinate during
the night is a sign of prostate cancer, when in
fact it is quite normal for older men to get up
once per night.
For those who are not bothered by their
LUTS, no treatment is needed, just reassur-
ance. But in men who do nd their LUTS
bothersome, individualized medical therapy
should be used to address each patients pre-
dominant symptoms. There are several phar-
macological treatment options that should be
used according the underling pathophysiol-
ogy. [BJU Int 2011;107:1426-1431] Symptoms
of overactive bladder are most oen treated
with antimuscarinic agents. Symptoms asso-
ciated with obstruction due to prostatic en-
largement can be relieved with -blockers.
In men with moderate-to-severe LUTS and
an enlarged prostate, 5-reductase inhibi-
tors (5ARIs) reduce prostate volume and de-
crease urethral obstruction, providing con-
tinual symptom improvement and reducing
the risk of AUR and the need for surgery.
Dutasteride/tamsulosin hydrochloride
Mode of action
Dutasteride-tamsulosin is a combination of
two drugs with complementary mechanisms
of action to improve symptoms in patients
with BPH. [Duodart Prescribing Information]
Tamsulosin is an -blocker. Its action is
inhibition of sympathetic stimulation via
1-adrenoceptors. This provides relief fromLUTS symptoms by relaxing smooth muscle
in the bladder neck, prostate and bladder de-
trusor.
Dutasteride is the only licensed type 1 and
type 2 dual 5ARI. [J Clin Endocrinol Metab
2004;89:2179-2184] 5ARIs block the conver-sion of testosterone to dihydrotestosterone
(DH), which is the androgen primarily re-
sponsible for hyperplasia of glandular pros-
tatic tissue. This signicantly reduces prostate
volume in men with BPH. The enzyme 5-al-
pha reductase is present throughout the body
in two forms, or iso-enzymes: type 1 and type
2. Type 1 has been reported to be located pre-
dominantly in the skin, both in hair follicles
and sebaceous glands, as well as in the liver,
prostate, and kidney. Type 2 is found in the
male genitalia and the prostate.
Clinical ecacy
Recently, the CombAT study showed that
combination therapy with the -blocker tam-
sulosin and the 5ARI dutasteride eectively
treats LUTS due to BPH. [J Urol 2008;179:616-
621] The study population consisted of men
aged 50 years and over with a clinical diag-
nosis of BPH by medical history and physi-
cal examination. Those with total serum
prostate-specic antigen (PSA) greater than
10.0 ng/mL, a history or evidence of prostate
cancer, previous prostatic surgery or a his-
tory of AUR within 3 months before studyentry were excluded from the study. Subjects
were randomized to receive either tamsulosin
(n=1,611), dutasteride (n=1,623) or the combi-
nation of the two agents (n=1,610). There were
comparable rates of discontinuation between
the three groups, and 79 percent of the pop-
ulation completed the 24-month follow-up
visit.
The primary endpoint was the self-admin-istered International Prostate Symptom Score
7/30/2019 Medical Tribune May 2013
26/39
26 May 2013 Drug Profile
(IPSS) questionnaire. At month 24, the aver-
age ( standard error) decreases in IPSS from
baseline were 6.2 ( 0.15) points for combina-
tion therapy versus 4.9 ( 0.15) and 4.3 ( 0.15)
points for dutasteride and tamsulosin, respec-tively. Compared with either monotherapy,
combination therapy also signicantly im-
proved urinary ow rate and reduced pros-
tate volume.
Adverse reactions
In the CombAT study, the total number of
drug-related adverse events (AEs) was higher
in the combination therapy group; however,
only 5 percent or fewer men withdrew from
the study due to an AE. The AEs more com-
mon with combination therapy were erectile
dysfunction, retrograde ejaculation, altered
(decreased) libido, ejaculation failure, de-
creased semen volume, loss of libido and nip-
ple pain. There were no instances of oppy
iris syndrome or breast neoplasms.
Dosing
The recommended dose of Duodart is one
capsule (500 g dutasteride /400 g tamsulo-
sin) taken orally approximately 30 minutes
aer the same meal each day. The eect of
renal impairment on the pharmacokinetics of
the active compounds has not been studied;
however, it is anticipated that no adjustment
in dosage would be needed. The medicationis contraindicated in patients with severe he-
patic impairment, and the eect of mild to
moderate hepatic impairment on pharmaco-
kinetics has not been studied.
Place within treatment guidelines
Guidelines published by the National In-
stitute for Health and Clinical Excellence
(NICE) state that men with moderate to se-
vere LUTS should be oered an -blocker.
A 5ARI should be oered to men with LUTS
who have prostates estimated to be larger
than 30 g or a PSA level greater than 1.4 ng/
mL, and who are considered to be at high risk
of progression (eg, older men). The combina-
tion of an -blocker and a 5ARI is therefore
appropriate for men with bothersome moder-
ate to severe LUTS and prostates estimated to
be larger than 30 g or a PSA level greater than
1.4 ng/mL. [The Management of Lower Urinary
Tract Symptoms in Men. National Clinical Guide-
line Centre, 2010.]
7/30/2019 Medical Tribune May 2013
27/39
27 May 2013 In Practice
Managing rist pain
Dr. Eugene WongConsultant Orthopedic & Spine SurgeonAdjunct Assistant Professor
Perdana University Graduate School of Medicine
Serdang, Selangor, Malaysia
The wrist joint is an area bounded by the
distal radius and ulna proximally, andthe bases of the metacarpals distally.
The joints around the wrist comprise of the
distal radioulnar, radiocarpal and midcarpal.
Each of the surrounding structures can be the
site of injury, degeneration or disease and,
thus, a source of pain.
The location of wrist pain is indicative of
the cause. Patients may present with swelling
and pain localized to the radial aspect, dorsalaspect, ulnar aspect, palmar aspect or gener-
alized wrist pain.
With careful history taking, thorough
physical examination and imaging techniques
(plain radiographs, ultrasonography and
bone scintigraphy), a diagnosis of the cause of
wrist pain can be made in 78 percent of cases.
As the wrist can be aected by a multitude
of local and general disorders, it is oen dif-
cult to make an accurate diagnosis. In the
literature, wrist pain is generally subdivided
into traumatic or nontraumatic origin.Tendonitis is a common problem that can
cause wrist pain and swelling. Wrist ten-
donitis is due to inammation of the tendon
sheath. Wrist sprains are common injuries to
the ligaments around the wrist joint.
In the case of tenosynovitis of extensor ten-
dons, there is pain in the dorsum of the wrist
that may radiate proximally and distally.
There is a history of repetitive activities andoveruse. Pain occurs on exion and resisted
extension. Treatment of wrist pain caused by
tendonitis usually does not require surgery.
In exor tenosynovitis, pain is located on the
palmar aspect of the wrist, is aggravated with
wrist motion and with resisted wrist exion.
Carpal tunnel syndrome is the most com-
mon compression neuropathy in the upper
extremity. In carpal tunnel syndrome, the me-dian nerve is compressed as it passes through
the wrist joint. Patients oen complain of pain
around the wrist, numbness and tingling in
the radial three digits, clumsiness and weak-
ness. Patients frequently wake up at night
with numbness in the ngers.
Tinel test of the carpal tunnel and Phalen test
may be positive. Decreased sensibility in me-
dian nerve distribution and thenar atrophy arelate signs. A cockup wrist splint can be used.
Activity modication can be tried in work-re-
lated carpal tunnel syndrome. Surgical release
of the transverse carpal ligament is performed
when non-operative measures have failed, in
patients with constant numbness, motor weak-
ness, or increased distal median nerve motor
latency noted on electromyography.
A ganglion cyst is a swelling that usually oc-
curs over the back of the hand or wrist. These
7/30/2019 Medical Tribune May 2013
28/39
28 May 2013 In Practice
are benign, uid-lled capsules. Ganglion
cysts are the most common mass on the dorsal
surface of the wrist. Most arise from the scaph-
olunate ligament. If the ganglion causes a pain
or severely limits activities, the uid may bedrained. Surgery involves removing the cyst
as well as part of the involved joint capsule or
tendon sheath. Even aer excision, there is a
small chance the ganglion will return.
Scaphoid fracture is most oen due to a fall
on an outstretched arm. There is tenderness
over the anatomic snuox. Undisplaced
fractures may be casted and a screw xation
done for displaced fractures.
Arthritis is a problem that can cause wrist
pain and diculty performing daily activi-
ties. Patients with inammatory arthritis and
osteoarthritis involving the radiocarpal, in-
tercarpal and carpometacarpal (CMC) joints
present with pain in the wrist.
Patients with osteoarthritis may have a
history of trauma. Swelling, stiness and de-
creased range of motion are present. Radio-
graphs of patients with osteoarthritis show
narrowing of the joint space, subchondral
sclerosis and osteophytes. Radiographs of pa-
tients with inammatory arthritis show nar-
rowing of joint space, osteopenia, bone ero-
sion and deformity. The arthritic carpal bones
can be excised. Joint fusion is done in cases
of severe pain. A wrist prosthetic implant isused to maintain pain-free range of motion.
De Quervain tenosynovitis is due to inam-
mation of the rst dorsal compartment of the
extensor tendons. There is a history of repeti-
tive wrist activities. The Finkelstein test (with
thumb exed into palm, pain is reproduced
by ulnar deviation of the wrist) is positive. An
anesthetic injection around the tendon sheath
can be given. Some patients may require sur-gical release of the rst dorsal compartment.
1. Scaphoid fracture 2. 1st CMC arthritis
3. Kienbocks disease 4. Carpal instability
5. TFCC tear
6. Ulnar impaction syndrome 7. De Quervain tenosynovitis
8. Pseudogout 9. Septic arthritic wrist
10. Ganglion cyst
7/30/2019 Medical Tribune May 2013
29/39
29 May 2013 In Practice
In cases of distal radioulnar joint instabil-
ity, pain is located at the distal radioulnar
joint, especially with pronation and supina-
tion. Pain at the exor carpi ulnar is usually
detected on resisted wrist exion and ulnardeviation.
A triangular brocartilage complex (TFCC)
tear presents with ulnar-sided wrist pain, of-
ten with clicking. Pain is experienced with
axial load while rotating the ulnar-deviated
wrist. An arthroscopic repair can be done.
Immunocompromised patients or those
with a history of intravenous drug use are
at higher risk of wrist infection than the gen-
eral population. Pain, swelling, erythema,
decreased range of motion (ROM) and other
cardinal signs of infection may be present.
Increased pain with ROM is characteristic.
Elevated leukocyte count, erythrocyte sedi-
mentation rate (ESR) and C-reactive protein
are signs of infection.
Finding the cause of wrist pain begins with
a detailed history, physical examination and
the use of several diagnostic tests. X-rays of
the wrist are usually a rst step and will help
determine if more tests are needed. An ultra-
sound scan can be used to diagnose tendon
tears around the wrist. Magnetic resonance
imaging (MRI) is commonly used to evaluate
the wrist because it can show abnormal areas
of the so tissues. Blood tests are done to lookfor infection or arthritis.
Plain anteroposterior, lateral and oblique
radiographs are obtained to look for fracture,
with a carpal tunnel view for fracture of the
hook of the hamate. A scaphoid view is used
to assess scaphoid fracture. MRI may be use-
ful in the diagnosis of TFCC tear and wrist
infection.
The treatment of wrist pain depends en-tirely on the cause of the problem.
Radial wrist pain:
De Quervain tenosynovitis
Scaphoid fracture or non-union
Thumb CMC arthritis
Radiocarpal arthritis
Dorsal wrist pain: Tenosynovitis of extensor tendons
Ganglion cyst
Extensor carpi ulnaris tendinitis
Ulnar wrist pain:
Distal radioulnar joint instability
Flexor carpi ulnaris tendinitis
Fracture of the hook of the hamate
TFCC tear
Palmar wrist pain:
Flexor tenosynovitis
Carpal tunnel syndrome (CTS)
Palmar ganglionGeneral wrist pain:
Arthritis
Infection
Table 1: Regional distribution of wrist pain.
Mechanical causes:
Fracture
Non-union of scaphoid or hook of the hamate
Avascular necrosis of the scaphoid (Preisers disease)
or lunate (Kienbcks disease).
Triangular brocartilage complex Distal radioulnar joint subluxation
Carpal instability
Scapholunate dissociation
De Quervains tenosynovitis
Intersection syndrome
Neoplasm or ganglion
Neurologic causes:
Distal posterior interosseous nerve syndrome
Injury of median nerve (carpal tunnel syndrome)
Injury of radial nerve
Injury of ulnar nerve (Guyons canal)
Thoracic outlet compression syndrome
Systemic causes:
Amyloidosis
Granulomatous disease (eg, sarcoid, tuberculosis)
Hematologic disease (eg, leukemia, multiple myeloma)
Metabolic conditions (eg, acromegaly, diabetes, gout,
hyperparathyroidism, hypocalcemia, hypothyroidism,
Pagets disease, pregnancy, pseudogout).
Osteomyelitis
Peripheral neuropathy
Reex sympathetic dystrophy (complex regional pain
syndrome).
Rheumatologic disorders (eg, psoriasis, rheumatoid
arthritis, scleroderma, systemic lupus erythematosus).Table 2: Etiology of wrist pain.
7/30/2019 Medical Tribune May 2013
30/39
30 May 2013 In Practice
Rest and activity modication: The rst
treatment for many common conditions
that cause wrist pain is to rest the joint, and
allow the acute inammation to subside. It
is important, however, to use caution whenresting the joint because prolonged immo-
bilization can cause a sti joint. Adjusting
activities so as not to irritate the joint can
help prevent worsening of wrist pain.
Ice and heat application: Ice packs and
heat pads are among the most commonly
used treatments for wrist pain.
Wrist support: Support braces can help pa-
tients who have either had a recent wrist
sprain injury or those who tend to injure
their wrists easily. These braces act as a gen-
tle support for wrist movements. They will
not prevent severe injuries, but may help
the patient perform simple activities while
rehabilitating from a wrist sprain.
Anti-inammatory medication: Nonste-
roidal anti-inammatory drugs (NSAIDs)
are some of the most commonly prescribed
medications, especially for patients with
wrist pain caused by arthritis and tendon-itis.
Cortisone injections: Cortisone is used to
treat inammation which is a common
problem in patients with wrist pain.
Some wrist conditions require arthroscopy
for diagnosis or treatment. Arthroscopic sur-
gery is a treatment option available for some
causes of wrist pain such as TFCC tear and
arthritis. In cases of severe pain arising from
arthritis, wrist replacement or fusion may be
required.
A detailed history taking, clinical exami-
nation and appropriate imaging will identify
the cause of wrist pain. Diagnostic injections
are sometimes needed.
7/30/2019 Medical Tribune May 2013
31/39
31 May 2013 After Hours
GettinG Around on the
London underGroundJoseph Hoye
There may be bigger and there may be
busier, but no one can deny the Lon-don Underground its place in history
as the worlds rst underground rail system.
It has inspired poetry, featured in lms and
been the subject of countless documentaries
and magazine articles. Reviled occasionally,
praised sporadically, it is the pulsing artery of
a sprawling city that depends on mass transit
to stay alive. For most Londoners, it is just a
fact of life. To visitors, it can be fascinating,horrifying and rewarding oen within the
same journey.
One hundred and y years ago, the
worlds rst underground railway opened.
The Metropolitan Railway hauled 38,000 pas-
sengers on its rst day in January 1863, travel-
ing the 6 kilometers between Paddington and
Farringdon. A broad gauge railway, the loco-
motives were steam powered and the wooden
carriages were illuminated by gas lamps.
Jump forward to today. From that single
line of 6 kilometers, there now runs 402 kilo-
meters of electried track with trains servic-
ing 270 stations across 26 London boroughsand into neighboring counties.
Its history and culture is rich. Ghosts
abound, civilians took shelter during bomb-
ing raids, US talk-show host Jerry Springer
was born in the Underground. Theres even
a book chronicling the mice of the Under-
ground. Ever wondered which station you
keep seeing in London lm sets? Good odds
that its the disused Aldwych station on thePiccadilly line. Patriot Games, V For Vendea
and Atonement are amongst the many lms
to use this station.
Using the Tube
With its bustling 3.5 million passengers
each day, it can be dicult to negotiate the
Tube. It may seem like chaos but the London
Underground does have an etiquee that
helps keep the system moving. Some of these
7/30/2019 Medical Tribune May 2013
32/39
7/30/2019 Medical Tribune May 2013
33/39
33 May 2013 After Hours
the Heathrow Express is out of action or the
motorways are snarled up.
London isnt just the inner city. Harrow,
Kew Gardens, Wimbledon and Europes larg-
est shopping centre Westeld Stratford areall directly accessible via the Tube.
There are occasions when the Under-
ground is not a travel option. London also
has a very good overland rail service as well
as an excellent bus service - some of the bus
routes operate a 24-hour service. Do not dis-
count Londons famous black cabs as a way
to move around the city but do be aware that
longer trips can be somewhat pricey and
trac holdups can last several hours. Fi-
nally, the River Thames is also a great option
for anyone wanting to move quickly or see
many of Londons famous landmarks. HMS
Belfast, originally a light cruiser for the Royal
Navy and now a museum ship permanently
moored on the river, is particularly daunting
when seen from the deck of a ferry.
And it is easy to walk the streets of Lon-
don. Wandering a 500 meter radius around
Trafalgar Square nets the National Gallery,Downing Street, Horse Guards, Piccadilly
Circus, Leicester Square, Covent Garden and
the Thames. Sometimes, Shanks pony is the
best way to get around London but for the
rest of the time, choose the Tube.
London has much to oer, whether you
live there or are just passing through for a
few days. Theaters, restaurants, football, mu-
seums: all are world class and all owe a debt
to the Underground. It is as much a part of
the city as the Tower of London or Tate Britain
and is rightly celebrating 150 years of service.
Used to get from A to B or enjoyed in its own
right, the Tube is Londons underground su-
perstar.
7/30/2019 Medical Tribune May 2013
34/39
34 May 2013 After Hours
BIkING THE
GOLDEN GATE BRIDGERadha Chitale
The Golden Gate Bridge cuts a russetswoop across the San Francisco skyline.Completed in 1937 to connect the main
part of the city to its rapidly expanding north-
ern counties, the bridge has always been opento pedestrian trac. Graced with sunny weath-er on a recent trip to San Francisco, I thoughtthe best way to experience this icon of modernarchitecture up close would be a leisurely cycle.
I started at Fishermans Wharf, the center ofSan Franciscos historical shing district and apopular tourist spot. The sta at Blazing Sad-dles, a bicycle rental company, outed me with
a bike, helmet, lock and water, and mapped outwhat would be a 13-kilometer ride hugging theSan Francisco Bay, across the bridge and downto Sausalito in Marin County where I could
catch a ferry back to the city. The whole ridewould take about 2-and-a-half hours.
The route to the bridge is mostly at butthere are several steep hills that I, less thantoned through the quadriceps, had to walk up.
The rst incline came almost immediately
aer I set o from Hyde Street. Pushing my bi-cycle up the hill did give me time to admire aclear view of the bay and Alcatraz Island, oncethe site of the famous high-security prison.
Beyond that rst very short hill was FortMason Green and further, Crissy Field, thenorthern edge of The Presidio park. The qui-et, green ride required no great eort, so Itook my time, snapping too many photos ofsailboats cuing through the bay.
Having rested suciently, I chose not toaempt the next and steepest portion of theride as the path climbs upwards in order to
7/30/2019 Medical Tribune May 2013
35/39
35 May 2013 After Hours
go from sea level to the base of the bridge 67meters above, and instead enjoyed watchingmore able cyclists chug past me.
The distinctive orange bridge loomed large
as soon as I crested the hill, a span suspensiondesign in which the roadway hangs o verti-cal suspenders aached to cables strung be-tween 227-meter high towers. The simple rail-ings, vertical ribbing and diminishing towersare hallmarks of art deco style, popular in the1930s. The whole structure looks delicate fromafar but the main cables are almost 1 meter indiameter and the total weight of the bridge isover 800,000 metric tons.
I made my way under the bridge to thewest side where cyclists could get on the foot-path. Safety signs warn about high windswhile crossing; but while the winds did notinterfere with my balance, I certainly couldhave used some gloves and an extra sweaterunder my down vest.
My discomfort was more than compensat-ed by the expanse of the Pacic Ocean and the
gentle green hills of Marin County. Some careis necessary when riding, as there are severalblind turns as the footpath curves around themain towers, but small outcroppings of foot-path allow a place to rest or take pictures clearof passing cyclists and pedestrians.
The gradual incline I felt as I pedaled start-ed to give as soon as I passed the halfwaypoint and I quickly reached the far side of the
bridge. Out of the sun it was chilly and I de-
bated continuing on to Sausalito, an unknownroute, or head back the way I came.
A fellow cyclist advised me to continueon and catch the ferry, saying it was an easy20-minute ride. In the future, I will be morewary of pro-looking cyclists in bright yellow
biking shorts who tell me a hill is not bigbecause once again I found myself pushingmy bicycle uphill. However, the subsequent
coast into picturesque Sausalito was enjoy-able.
With just enough time for a restorativecoee, I caught the last ferry back to thePort of San Francisco. I hopped on my bikeagain and cycled up the Embarcadero back
to Fishermans Wharf to return it, 4 hoursaer I began.
DID YOu kNOw?The Golden Gate Bridge has always been
painted International Orange, chosen tocomplement the warm colors of the sur-rounding land masses and contrast withthe cool blues of sea and sky, which alsomakes it more visible to passing shipsthrough the Bay fog.The bridge towers have fewer lights to-wards the top to appear more majestic atnight, as if they soared beyond illumina-
tion.The Golden Gate Bridge was only the lon-gest suspension bridge in the world until1964, but it is still the most photographed
bridge in the world.The bridge can expand or contract by upto 16 feet when the temperature changes.It has appeared prominently in a numberof lms including Superman (1978), Inter-view with a Vampire (1994) and The Rock
(1996).
7/30/2019 Medical Tribune May 2013
36/39
36 May 2013 Humor
I think, if u lsen ur belt a little,u wnt be exerienin thse terrible hest ains!
Dnt tr t hide under thse masks. I knw wh u are!
Whatever it is in arund,u have it!
Just make sure u dnt takethese sleein ills and a laxative
n the same niht!
She an frive Lane Armstrnbut she ant frive me!
I knw u must be in a lt fain, but lets be ttall fair.
This is ur niht t d the dishes!
7/30/2019 Medical Tribune May 2013
37/39
37 May 2013 Calendar
MAy
American Urology Association (AUA) Annual
Meeting
4/5/2013 to 8/5/2013
Location: San Diego, California, USInfo: AUATel: (1) 410 689 3700Fax: (1) 410 689 3800Email: customerservice@AUAnet.orgWebsite: www.aua2013.org
46th Annual Meeting o the European Society
or Paediatric Gastroenterology, Hepatology and
Nutrition
8/5/2013 to 11/5/2013Location: London, EnglandInfo: ESPGHAN Organizers
Tel: (44) 845 1800 360Email: ESP2013-Reg@mci-group.comWebsite: www.espghan2013.org
9th Asian Society or Paediatric Research
Congress
9/5/2013 to 12/5/2013Location: Kuching, MalaysiaInfo: ASPR-PSM 2013 Congress SecretariatTel: (603) 4023 4700, 4025 4700, 4025 3700Website: www.aspr-psm2013.org
20th European Congress on Obesity
12/5/2013 to 15/5/2013Location: Liverpool, EnglandInfo: ECO2013 SecretariatTel: (44) 20 8973 2506Email: enquiries@easo.orgWebsite: www.easo.org/liverpool-eco-2013
Diabetes Preventing the Preventables Forum
24/5/2013 to 26/5/2013Location: Kuala Lumpur, MalaysiaInfo: Asia Diabetes FoundationTel: (852) 2637 6624
Fax: (852) 2647 6624Email: enquiry@adf.org.hkWebsite: www.adf.org.hk/dpp2013
12th Congress o the European Association or
Palliative Care
30/5/2013 to 2/6/2013Location: Prague, Czech RepublicInfo: European Association for Palliative CareTel: (49) 89 548234 62Fax: (49) 89 54823443Email: eapc2013@interplan.deWebsite: www.eapc-2013.org
American Society o Clinical Oncology Annual
Meeting
31/5/2013 to 4/6/2013Location: Chicago, Illinois, USInfo: ASCO Customer CareTel: (1) 888 282 2552 or
(1) 571 483 1300Website: http://chicago2013.asco.org
World Congress o Nephrology
31/5/2013 to 4/6/2013Location: Hong KongInfo: ISN World Congress of Nephrology 2013Tel: (852) 2559 9973Fax: (852) 2547 9528Email: registration@wcn2013.orgWebsite: www.wcn2013.org
JUNE23rd Conerence o the Asian Pacifc Association
or the Study o the Liver
6/6/2013 to 9/6/2013Location: SingaporeInfo: APASL SecretariatEmail: apaslconference@kenes.comWebsite: www.apaslconference.org
International Digestive Disease Forum 2013
8/6/2013 to 9/6/2013
Location: Hong KongInfo: UBM Medica Pacific LimitedTel: (852) 2155 8557Fax: (852) 2559 6910Email: info@iddforum.comWebsite: www.iddforum.com
3rd World Congress o Thoracic Imaging
8/6/2013 to 11/6/2013Location: Seoul, KoreaInfo: WCTI SecretariatTel: (82) 2 3452 7245/(82) 2 3471 8555Fax: (82) 2 521 8683
Email: wcti2013@insession.co.krWebsite: www.wcti2013.org
17th International Congress o Parkinsons
Disease and Movement Disorders
16/6/2013 to 20/6/2013Location: Sydney, AustraliaInfo: MDS Congress StaffTel: (1) 414 276 2145Fax: (1) 414 276 3349Email: congress@movementdisorders.orgWebsite: www.mdscongress2013.org
7/30/2019 Medical Tribune May 2013
38/39
38 May 2013 Calendar
American Diabetes Association
73rd Scientifc Sessions
21/6/213 to 25/6/2013Location: Chicago, Illinois, USInfo: ADA Registration Customer Care CenterTel: (1) 415 268 2086
Email: ADAReg@cmrus.comWebsite: http://scientificsessions.diabetes.org
UpcoMINg
9th Asian Dermatological Congress
10/7/2013 to 13/7/2013Location: Hong KongInfo: ADC 2013 SecretariatTel: (852) 3151 8900Email: adc2013@swiretravel.com
Website: www.adc2013.org
13th Asian Federation o Sports Medicine
Congress
25/9/2013 to 28/9/2013Location: Kuala Lumpur, MalaysiaInfo: AFSM OrganizersEmail: 13afsm@gmail.com
Website: www.13afsm.com
13th International Workshop on Cardiac
Arrhythmias - VeniceArrhythmias 2013
27/10/2013 to 29/10/2013Location: Venice, ItalyInfo: VeniceArrhythmias 2013 Organizing SecretariatTel: (39) 0541 305830Fax: (39) 0541 305842Email: info@venicearrhythmias.orgWebsite: www.venicearrhythmias.org
READ JPOG ANYTIME, ANYWHERE.Download the digital edition today at www.jpog.com
7/30/2019 Medical Tribune May 2013
39/39
Publisher : Ben Yeo
Managing Editor : Greg Town
Senior Editor : Christina Lau
Contributing Editors : Saras Ramiya, Leonard Yap,
Pank Jit Sin, Malvinderjit Kaur
Dhillon (Malaysia), Yves St.
James Aquino, M.D. (Philippines),
Radha Chitale, Elvira Manzano,
Rajesh Kumar, Grace Ling
(Singapore)
Publication Manager : Marisa Lam
Designers : Razli Rahman, Charity Chan,Lisa Low, Joseph Nacpil,
Agnes Chieng, Sam Shum,
Cindy Ang, Sharen Lee
Production : Edwin Yu, Ho Wai Hung,
Jasmine Chay
Circulation Executive : Christine Chok
Accounting Manager : Minty Kwan
Advertising Co-ordinator : Rachael Tan
Published by : MIMS Pte Ltd27th Floor, OTB Building,
160 Gloucester Road,
Wanchai, Hong Kong
Tel: (852) 2559 5888
Fax: (852) 2559 6910
Email: enquiry@medicaltribune.com
Advertising Enquiries:
China : Yang Xuan
Tel: (8621) 6157 3888
Email: enquiry.cn@mims.com
Hong Kong : Kristina Lo-Kurtz, Miranda Wong,Marisa Lam, Jacqueline Cheung
Tel: (852) 2559 5888
Email: enquiry.hk@mims.com
India : Monica Bhatia
Tel: (9180) 2349 4644
Email: enquiry.in@mims.com
Indonesia : Cliford Patrick
Tel: (6221) 729 2662
Email: enquiry id@mims com
Malaysia : Lee Pek Lian, Sumitra Pakry,
Grace Yeoh
Tel: (603) 7954 2910
Email: enquiry.my@mims.com
Philippines : Marian Chua, Kim Pagsuyuin,
Rowena Belgica, Philip Katipunan
Tel: (632) 886 0333
Email: enquiry.ph@mims.com
Singapore : Jason Bernstein, Carrie Ong,
Josephine Cheong, Melanie Nyam
Tel: (65) 6290 7400
Email: enquiry.sg@mims.com
Thailand : Wipa Sriwijitchok
Tel: (662) 741 5354Email: enquiry.th@mims.com
Vietnam : Nguyen Thi Lan Huong, Nguyen Thi My Dung
Tel: (848) 3829 7923
Email: enquiry.vn@mims.com
Europe/USA : Kristina Lo-Kurtz
Tel: (852) 2116 4352
Email: kristina.lokurtz@mims.com
Medical Tribune is published 12 times a year (23 times in Malaysia) by
MIMS Pte Ltd. Medical Tribune is on controlled circulation publication tomedical practitioners in Asia. It is also available on subscription to members
of allied professions. The price per annum is US$48 (surface mail) and
US$60 (overseas airmail); back issues at US$5 per copy. Editorial matter
published herein has been prepared by professional editorial staff. Views
expressed are not necessarily those of MIMS Pte Ltd. Although great
effort has been made in compiling and checking the information given
in this publication to ensure that it is accurate, the authors, the publisher
and their servants or agents shall not be responsible or in any way liable
for the continued currency of the information or for any errors, omissions
or inaccuracies in this publication whether arising from negligence or
otherwise howsoever, or for any consequences arising therefrom. The
inclusion or exclusion of any product does not mean that the publisher
advocates or rejects its use either generally or in any particular field or
fields. The information contained within should not be relied upon solely
for final treatment decisions.
2013 MIMS Pte Ltd. All rights reserved. No part of this publication
may be reproduced in any language, stored in or introduced into a
retrieval system, or transmitted, in any form or by any means (electronic,
mechanical, photocopying, recording or otherwise), without the written
consent of the copyright owner. Permission to reprint must be obtained
from the publisher. Advertisements are subject to editorial acceptance
and have no influence on editorial content or presentation. MIMS Pte
Ltd does not guarantee, directly or indirectly, the quality or efficacy of
any product or service described in the advertisements or other material
which is commercial in nature.
Philippine edition: Entered as second class mail at the Makati Central
Recommended